BMO Capital Starts Nightstar Therapeutics (NITE) at Outperform

BMO Capital initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $30.00.

Analyst Matt Luchini believes the NSR-REP1 drug could transform the treatment of choroideremia and forecasts a market opportunity of $710 million. The analyst also sees upside from the company second gene therapy program NSR-RPGR for XLP which could see a peak sales opportunity of $675 million.

For an analyst ratings summary and ratings history on Nightstar Therapeutics click here. For more ratings news on Nightstar Therapeutics click here.

Shares of Nightstar Therapeutics closed at $19.00 Friday.

You May Also Be Interested In

• Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
• WaterBridge Infrastructure (WBI) PT Raised to $40 at Raymond James
• BMO Capital Starts Cadillac Mines Corp (CADY:CN) at Outperform